| The long-overdue haircuts are being booked in. Much-missed friends are planning garden get-togethers. And pubs across Britain are dusting off their taps in preparation for a summer like no other.
Brighter days are well on their way. With so much to look forward to, it’s never been more important to stay connected to the stories and subjects that you care about - and make the absolute most of our brave new world.
Our award-winning journalists are here to help you do just that. Join us today and you can choose from two exceptional subscription offers.
Enjoy a one-year subscription for just 39, saving you 63%.
Or try one month free, then your next three months for just 1 a month. You can read on for only 2 a week and cancel at any time.
As a Telegraph subscriber, you’ll be kept expertly informed on every critical step as we move towards life beyond restrictions. Several major European nations have suspended use of the AstraZeneca inoculation, this week, citing concerns over blood clots. The move has caused chaos in some EU countries, with Italy’s medicines regulator admitting that the move was a “political decision” while Angela Merkel’s government is at war over the “disaster”.
The Telegraph’s Sarah Knapton has analysed the statistics behind the fears, writing “Should Britons be worried about the safety of the AstraZeneca jab? The numbers suggest not”. Indeed, just a few days ago, the World Health Organisation said that countries should keep using the vaccine. The European Commission has also hit out at EU nations for hoarding unused Covid-19 jabs, with less than half of the delivered AstraZeneca inoculations being used.
Ambrose Evans-Pritchard admonishes this “European misgovernment”, warning that “The precautionary principle is literally killing Europe”. Ross Clark provides exceptional insight as he states that “Europe's big problem now is that it lacks a clear alternative to AstraZeneca”.
Jeremy Warner reflects on the anniversary of lockdown, writing “A year on, it’s Europe in the dock over Covid – not once-fallible Britain”. Charles Moore, meanwhile, offers his own compelling thoughts on the milestone, commenting that “After a year of Covid, we have seen the worst but also celebrated the very best”.
Boris Johnson has revealed his vision for a “match-fit” Britain in the post-Brexit world, this week, following a months-long rethink of the Government’s defence, security and foreign policy. Some Conservative MPs attacked the Prime Minister’s “grasping naivety” on China, while the review also included plans to expand the UK’s nuclear weapons stockpile by over 40 per cent.
Michael Deacon offers a wry, incisive reaction to Sir Keir Starmer’s response in the Commons, writing “Jeremy Corbyn’s legacy will haunt Labour for years to come... and this debate showed why”. William Hague shares a balanced, experienced perspective on the Prime Minister’s “unprecedented foreign policy challenge” as he states “We can cope with the rise of China, but it will take a unique approach”.
You’ll be kept in the know on all the latest royal turmoil, as the Duke and Duchess of Sussex accuse Buckingham Palace of continuing to leak stories. You’ll also be sure of up-to-the-minute travel news, with foreign holidays potentially pushed back until after the May half-term. And don’t miss Tom Hodgkinson’s eye-opening guide to Peopleton, “the nastiest village in Worcestershire” where “neighbourliness has been killed off by Covid”.
You can rest assured that you’ll find a much friendlier community in the subscriber-exclusive comments section of our website. Over 300 Telegraph subscribers have already had their say on Allison Pearson’s brilliant, illuminating article, “Good men joining forces with women is the only way we will ever walk the streets without fear”. Join us today and your thoughts would be assured of a warm welcome, too.
Subscribe now to seal your saving in place and unlock unlimited access to our unrivalled journalism with a great-value Standard Digital Subscription.
Enjoy one whole year of award-winning reporting for just 39, saving you an exceptional 63% over 12 months. |
